Follow us on Google for the latest stock newsFollow Seeking Alpha on Google for the latest stock newsPlay Earnings CallPlay Earnings Call
Sartorius Stedim Biotech S.A. (SRTOY) Q1 2026 Earnings Call April 23, 2026 7:00 AM EDT
Company Participants
Petra Muller – Head of Investor Relations
Michael Grosse – CEO & Chairman of the Executive Board
Florian Funck – CFO & Member of Executive Board
Rene Faber – Head of Bioprocess Solutions Division & Member of Executive Board
Conference Call Participants
Zain Ebrahim – JPMorgan Chase & Co, Research Division
Douglas Schenkel – Wolfe Research, LLC
Subhalaxmi Nambi – Guggenheim Securities, LLC, Research Division
Charles Pitman – Barclays Bank PLC, Research Division
Charlie Haywood – BofA Securities, Research Division
Charles Weston – RBC Capital Markets, Research Division
Oliver Metzger – ODDO BHF Corporate & Markets, Research Division
Odysseas Manesiotis – BNP Paribas, Research Division
Thibault Boutherin – Morgan Stanley, Research Division
James Vane-Tempest – Jefferies LLC, Research Division
Naresh Chouhan – Intron Health Advisors Ltd
Falko Friedrichs – Deutsche Bank AG, Research Division
Delphine Le Louet – Bernstein Institutional Services LLC, Research Division
Presentation
Operator
Ladies and gentlemen welcome to the Sartorius and Sartorius Stedim Biotech Conference Call and Live Webcast on Q1 2026. I’m Moritz, your Chorus Call operator. [Operator Instructions] I would now like to turn the conference over to Petra Muller, Head of Investor Relations of Sartorius. Please go ahead.
Petra Muller
Head of Investor Relations
Thank you. Hello, and a warm welcome also from my side. I’m joined today by our CEO, Michael Grosse; by Florian Funck, our CFO; Rene Faber, Head of the Bioprocessing Division and CEO of Sartorius Stedim Biotech; and by Alexandra Gatzemeyer, Head of our LPS division.
As always, we will start with prepared remarks followed by the Q&A session. [Operator Instructions]. Please note that management comments during this call will be include forward-looking statements that involve risks and uncertainties. For a discussion of risk factors, I encourage you to review the safe harbor statement contained in today’s press release and the
